Stockscreener 앱 받기
1.05
6.25%
-0.07
시간 외 거래:
1.04
-0.01
-0.95%
전일 마감가:
$1.12
열려 있는:
$1.11
하루 거래량:
296.02K
Relative Volume:
1.07
시가총액:
$22.67M
수익:
-
순이익/손실:
$-8.32M
주가수익비율:
-2.1802
EPS:
-0.4816
순현금흐름:
$-7.43M
1주 성능:
-9.48%
1개월 성능:
+3.96%
6개월 성능:
-28.57%
1년 성능:
-18.60%
1일 변동 폭
$1.00
$1.11
1주일 범위
$1.00
$1.22
52주 변동 폭
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
명칭
NanoViricides Inc
전화
203-937-6137
주소
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
1.05 | 24.19M | 0 | -8.32M | -7.43M | -0.4816 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-16 | 개시 | Alliance Global Partners | Buy |
| 2015-02-11 | 개시 | Midtown Partners | Strong Buy |
NanoViricides Inc 주식(NNVC)의 최신 뉴스
EBITDA per share of NanoViricides, Inc. – FWB:NV3P - TradingView
Volume Recap: Can NanoViricides Inc grow without external funding2026 Momentum Check & Consistent Return Strategy Ideas - baoquankhu1.vn
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Beaver County Times
In Treating Measles Infection, NV-387 Showed Strong Antiviral Activity, and Significantly, Protected Lungs from Damage, Describes NanoViricides - The Register-Guard
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - The Asheville Citizen Times
NanoViricides Completes Manufacturing of NV-387 Oral Gummies, Prepares for Phase II Monkeypox Trial - citybuzz -
Aug Setups: Can NanoViricides Inc continue delivering strong returns2026 EndofMonth & Stepwise Trade Execution Plans - baoquankhu1.vn
Small cap wrap: NanoViricides, Millennial Potash, Gunnison Copper, Century Lithium… - Proactive Investors
NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial - Yahoo! Finance Canada
NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete - Durham Herald Sun
Antiviral NV-387 heads to Phase II mpox trial with new gummy form - Stock Titan
Jobs Data: Can NanoViricides Inc continue delivering strong returnsMarket Volume Report & Community Verified Trade Signals - baoquankhu1.vn
Sell Signal: Is NanoViricides Inc subject to activist investor interest2025 Investor Takeaways & Low Risk Growth Stock Ideas - baoquankhu1.vn
NNVC Earnings History & Surprises | EPS & Revenue Results | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
NanoViricides to Present at the PODD 2025 Conference in Boston on October 27 - The Asheville Citizen Times
getLinesFromResByArray error: size == 0 What is NanoViricides Inc.’s TAM (Total Addressable Market)Portfolio Gains Report & Growth Focused Entry Reports - mfd.ru
US Stocks Recap: Is NanoViricides Inc forming a breakout patternJuly 2025 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
Aug Fed Impact: Can NanoViricides Inc continue delivering strong returnsQuarterly Earnings Report & Long-Term Safe Investment Plans - baoquankhu1.vn
NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387ICYMI - Proactive financial news
Growth Value: Will NanoViricides Inc benefit from rate cutsJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Small cap wrap: Aftermath Silver, M2i Global, NanoViricides, AtaiBeckley… - Proactive financial news
NanoViricides advances toward fully funded Phase II MPox trial in DRC - Proactive financial news
NanoViricides advances broad-spectrum antiviral NV-387 towards Phase II MPox study - Yahoo Finance
NanoViricides: Fiscal Q2 Earnings Snapshot - kare11.com
NanoViricides: Fiscal Second Quarter Earnings Overview - Bitget
Moving Averages: Is NanoViricides Inc exposed to political riskJuly 2025 Movers & Growth Focused Stock Reports - baoquankhu1.vn
Can NanoViricides Inc grow without external fundingJuly 2025 Review & Growth Focused Stock Reports - baoquankhu1.vn
Small cap wrap: BioVie, VivoPower, NanoViricides, Aftermath Silver... - Proactive financial news
NanoViricides seeks FDA orphan status for MPox drug - Yahoo Finance
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Bitget
New Mpox drug candidate NV-387 chases FDA orphan status - Stock Titan
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX) - Barchart.com
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza WaveNV-387 is Effective Against H3N2 - Ventura County Star
Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials… - Proactive Investors
Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - USA Today
NanoViricides seeks orphan drug status with US FDA for measles treatment - Yahoo Finance
Measles cases surge as NanoViricides seeks orphan status for NV-387 - Stock Titan
NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres - USA Today
Trading Recap: Is NanoViricides Inc part of any ETFJuly 2025 Drop Watch & Real-Time Buy Signal Alerts - baoquankhu1.vn
CEO Change: Is NanoViricides Inc undervalued by DCF analysisWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Reno Gazette Journal
NanoViricides President Discusses Broad-Spectrum Antiviral Platform and Upcoming Phase II Trial for MPox Treatment - citybuzz -
NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres - accessnewswire.com
Inside a single antiviral drug aimed at flu, COVID, RSV and Mpox - Stock Titan
NanoViricides Inc (NNVC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):